ChromaDex surges on surprise Q3 profit

Niagen Bioscience

01/11/2024 13:05

** Biotech co ChromaDex's  CDXC.O  shares rise ~17.7% to
$4.10 premarket
    ** CDXC, late on Thursday, reported Q3 profit of 2 cents/shr
vs analysts' estimate of breakeven - LSEG data
    ** Co's Q3 revenue of $25.58 mln beat analysts' estimate of
$23.64 mln on strong demand for its NAD (nicotinamide adenine
dinucleotide) supplement
    ** NAD is an essential coenzyme that is a key regulator of
cellular metabolism and is found in every cell of the human body
    ** Up to last close, stock more than doubled YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))